Open Access 10-04-2025 | Histiocytosis | ORIGINAL ARTICLE

Histiocytoses and reactive proliferations of histiocytes: current state of the art and evolving concepts—a report from the joint CSHP-EA4HP-SH workshop 2024, Hefei, China

Authors: Falko Fend, Stefan Dirnhofer, Caoimhe Egan, Sophie Song, Zhe Wang, Xiaoqiu Li, Weiping Liu, Wenbin Xiao, Jean-Francois Emile, John Goodlad, Robert Lorsbach

Published in: Virchows Archiv

Abstract

Reactive and clonal proliferations of histiocytes (macrophages/dendritic cells) represent a broad spectrum of disorders, which can affect virtually any organ of the body. The clinical spectrum ranges from benign, localized and self-limiting manifestations to severe multi-system disease. Hemophagocytic lymphohistiocytosis (HLH) is a frequently life-threatening, systemic hyperinflammatory process triggered by massive cytokine release by activated, reactive macrophages. Familial and secondary forms of HLH are discerned. Histiocytoses are clonal inflammatory myeloid disorders characterized by proliferations of mature histiocytes/macrophages and dendritic cells with recurrent kinase-activating mutations which result in constitutive activation of the ERK signaling pathway. Although traditionally subclassified according to the phenotype of the lesional cells, the clonal cells can show significant plasticity, and the occurrence of mixed histiocytoses is increasingly recognized. This is in part due to their derivation from a myeloid progenitor cell and explains the frequent association with clonal hematopoiesis or overt myeloid neoplasms in adults. At the joint Workshop of the Chinese Society of Hematopathology, the European Association for Haematopathology and the Society for Hematopathology on histiocytic/dendritic cell proliferations, neoplasms, and their mimics in Hefei, China, April 2024, in sessions 1 and 2 a total of 8 cases of HLH, 9 cases of reactive histiocytic proliferations and 40 cases of histiocytoses were submitted and reviewed by the panel. The latter included cases of LCH, indeterminate cell histiocytosis, Erdheim Chester disease, juvenile xanthogranuloma, Rosai Dorfman disease, multicentric reticulohistiocytosis, ALK-positive histiocytosis, and mixed histiocytoses. The present report summarizes important findings and open questions arising from discussing the workshop cases.

Available only for authorised users

Emile JF, Cohen-Aubart F, Collin M, Fraitag S, Idbaih A, Abdel-Wahab O, Rollins BJ, Donadieu J, Haroche J (2021) Histiocytosis. Lancet 398:157–170. https://doi.org/10.1016/S0140-6736(21)00311-1CrossRefPubMedPubMedCentral

Haroche J, Cohen-Aubart F, Rollins BJ, Donadieu J, Charlotte F, Idbaih A, Vaglio A, Abdel-Wahab O, Emile JF, Amoura Z (2017) Histiocytoses: emerging neoplasia behind inflammation. Lancet Oncol 18:e113–e125. https://doi.org/10.1016/S1470-2045(17)30031-1CrossRefPubMed

McClain KL, Bigenwald C, Collin M, Haroche J, Marsh RA, Merad M, Picarsic J, Ribeiro KB, Allen CE (2021) Histiocytic disorders. Nat Rev Dis Primers 7:73. https://doi.org/10.1038/s41572-021-00307-9CrossRefPubMedPubMedCentral

(1987) Histiocytosis syndromes in children. Writing group of the histiocyte society. Lancet (London, England) 1:208–209

Badalian-Very G, Vergilio JA, Degar BA, MacConaill LE, Brandner B, Calicchio ML, Kuo FC, Ligon AH, Stevenson KE, Kehoe SM, Garraway LA, Hahn WC, Meyerson M, Fleming MD, Rollins BJ (2010) Recurrent BRAF mutations in Langerhans cell histiocytosis. Blood 116:1919–1923. https://doi.org/10.1182/blood-2010-04-279083CrossRefPubMedPubMedCentral

Brown RA, Kwong BY, McCalmont TH, Ragsdale B, Ma L, Cheung C, Rieger KE, Arber DA, Kim J (2015) ETV3-NCOA2 in indeterminate cell histiocytosis: clonal translocation supports sui generis. Blood 126:2344–2345. https://doi.org/10.1182/blood-2015-07-655530CrossRefPubMed

Brown NA, Furtado LV, Betz BL, Kiel MJ, Weigelin HC, Lim MS, Elenitoba-Johnson KS (2014) High prevalence of somatic MAP2K1 mutations in BRAF V600E-negative Langerhans cell histiocytosis. Blood 124:1655–1658. https://doi.org/10.1182/blood-2014-05-577361CrossRefPubMed

Chakraborty R, Hampton OA, Shen X, Simko SJ, Shih A, Abhyankar H, Lim KP, Covington KR, Trevino L, Dewal N, Muzny DM, Doddapaneni H, Hu J, Wang L, Lupo PJ, Hicks MJ, Bonilla DL, Dwyer KC, Berres ML, Poulikakos PI, Merad M, McClain KL, Wheeler DA, Allen CE, Parsons DW (2014) Mutually exclusive recurrent somatic mutations in MAP2K1 and BRAF support a central role for ERK activation in LCH pathogenesis. Blood 124:3007–3015. https://doi.org/10.1182/blood-2014-05-577825CrossRefPubMedPubMedCentral

Diamond EL, Durham BH, Haroche J, Yao Z, Ma J, Parikh SA, Wang Z, Choi J, Kim E, Cohen-Aubart F, Lee SC, Gao Y, Micol JB, Campbell P, Walsh MP, Sylvester B, Dolgalev I, Aminova O, Heguy A, Zappile P, Nakitandwe J, Ganzel C, Dalton JD, Ellison DW, Estrada-Veras J, Lacouture M, Gahl WA, Stephens PJ, Miller VA, Ross JS, Ali SM, Briggs SR, Fasan O, Block J, Heritier S, Donadieu J, Solit DB, Hyman DM, Baselga J, Janku F, Taylor BS, Park CY, Amoura Z, Dogan A, Emile JF, Rosen N, Gruber TA, Abdel-Wahab O (2016) Diverse and targetable kinase alterations drive histiocytic neoplasms. Cancer Discov 6:154–165. https://doi.org/10.1158/2159-8290.CD-15-0913CrossRefPubMed

10.

Haroche J, Charlotte F, Arnaud L, von Deimling A, Helias-Rodzewicz Z, Hervier B, Cohen-Aubart F, Launay D, Lesot A, Mokhtari K, Canioni D, Galmiche L, Rose C, Schmalzing M, Croockewit S, Kambouchner M, Copin MC, Fraitag S, Sahm F, Brousse N, Amoura Z, Donadieu J, Emile JF (2012) High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-Langerhans cell histiocytoses. Blood 120:2700–2703. https://doi.org/10.1182/blood-2012-05-430140CrossRefPubMed

11.

Haroche J, Cohen-Aubart F, Emile JF, Arnaud L, Maksud P, Charlotte F, Cluzel P, Drier A, Hervier B, Benameur N, Besnard S, Donadieu J, Amoura Z (2013) Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim-Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutation. Blood 121:1495–1500. https://doi.org/10.1182/blood-2012-07-446286CrossRefPubMed

12.

Berres ML, Lim KP, Peters T, Price J, Takizawa H, Salmon H, Idoyaga J, Ruzo A, Lupo PJ, Hicks MJ, Shih A, Simko SJ, Abhyankar H, Chakraborty R, Leboeuf M, Beltrao M, Lira SA, Heym KM, Bigley V, Collin M, Manz MG, McClain K, Merad M, Allen CE (2014) BRAF-V600E expression in precursor versus differentiated dendritic cells defines clinically distinct LCH risk groups. J Exp Med 211:669–683. https://doi.org/10.1084/jem.20130977CrossRefPubMedPubMedCentral

13.

Heritier S, Emile JF, Barkaoui MA, Thomas C, Fraitag S, Boudjemaa S, Renaud F, Moreau A, Peuchmaur M, Chassagne-Clement C, Dijoud F, Rigau V, Moshous D, Lambilliotte A, Mazingue F, Kebaili K, Miron J, Jeziorski E, Plat G, Aladjidi N, Ferster A, Pacquement H, Galambrun C, Brugieres L, Leverger G, Mansuy L, Paillard C, Deville A, Armari-Alla C, Lutun A, Gillibert-Yvert M, Stephan JL, Cohen-Aubart F, Haroche J, Pellier I, Millot F, Lescoeur B, Gandemer V, Bodemer C, Lacave R, Helias-Rodzewicz Z, Taly V, Geissmann F, Donadieu J (2016) BRAF mutation correlates with high-risk langerhans cell histiocytosis and increased resistance to first-line therapy. J Clin Oncol 34:3023–3030. https://doi.org/10.1200/JCO.2015.65.9508CrossRefPubMedPubMedCentral

14.

Hervier B, Haroche J, Arnaud L, Charlotte F, Donadieu J, Neel A, Lifermann F, Villabona C, Graffin B, Hermine O, Rigolet A, Roubille C, Hachulla E, Carmoi T, Bezier M, Meignin V, Conrad M, Marie L, Kostrzewa E, Michot JM, Barete S, Taly V, Cury K, Emile JF, Amoura Z, French Histiocytoses Study G (2014) Association of both Langerhans cell histiocytosis and Erdheim-Chester disease linked to the BRAFV600E mutation. Blood 124:1119–1126. https://doi.org/10.1182/blood-2013-12-543793CrossRefPubMed

15.

Cohen Aubart F, Roos-Weil D, Armand M, Marceau-Renaut A, Emile JF, Duployez N, Charlotte F, Poulain S, Lhote R, Helias-Rodzewicz Z, Della-Valle V, Bernard O, Maloum K, Nguyen-Khac F, Donadieu J, Amoura Z, Abdel-Wahab O, Haroche J (2021) High frequency of clonal hematopoiesis in Erdheim-Chester disease. Blood 137:485–492. https://doi.org/10.1182/blood.2020005101CrossRefPubMedPubMedCentral

16.

Durham BH, Roos-Weil D, Baillou C, Cohen-Aubart F, Yoshimi A, Miyara M, Papo M, Helias-Rodzewicz Z, Terrones N, Ozkaya N, Dogan A, Rampal R, Urbain F, Le Fevre L, Diamond EL, Park CY, Papo T, Charlotte F, Gorochov G, Taly V, Bernard OA, Amoura Z, Abdel-Wahab O, Lemoine FM, Haroche J, Emile JF (2017) Functional evidence for derivation of systemic histiocytic neoplasms from hematopoietic stem/progenitor cells. Blood 130:176–180. https://doi.org/10.1182/blood-2016-12-757377CrossRefPubMedPubMedCentral

17.

Kemps PG, Kester L, Scheijde-Vermeulen MA, van Noesel CJM, Verdijk RM, Diepstra A, van Marion AMW, Dors N, van den Bos C, Bruggink AH, Hogendoorn PCW, van Halteren AGS (2024) Demographics and additional haematologic cancers of patients with histiocytic/dendritic cell neoplasms. Histopathology 84:837–846. https://doi.org/10.1111/his.15127CrossRefPubMed

18.

Papo M, Diamond EL, Cohen-Aubart F, Emile JF, Roos-Weil D, Gupta N, Durham BH, Ozkaya N, Dogan A, Ulaner GA, Rampal R, Kahn JE, Sene T, Charlotte F, Hervier B, Besnard C, Bernard OA, Settegrana C, Droin N, Helias-Rodzewicz Z, Amoura Z, Abdel-Wahab O, Haroche J (2017) High prevalence of myeloid neoplasms in adults with non-Langerhans cell histiocytosis. Blood 130:1007–1013. https://doi.org/10.1182/blood-2017-01-761718CrossRefPubMedPubMedCentral

19.

Bigenwald C, Le Berichel J, Wilk CM, Chakraborty R, Chen ST, Tabachnikova A, Mancusi R, Abhyankar H, Casanova-Acebes M, Laface I, Akturk G, Jobson J, Karoulia Z, Martin JC, Grout J, Rafiei A, Lin H, Manz MG, Baccarini A, Poulikakos PI, Brown BD, Gnjatic S, Lujambio A, McClain KL, Picarsic J, Allen CE, Merad M (2021) BRAF(V600E)-induced senescence drives Langerhans cell histiocytosis pathophysiology. Nat Med 27:851–861. https://doi.org/10.1038/s41591-021-01304-xCrossRefPubMedPubMedCentral

20.

Tzankov A, Kremer M, Leguit R, Orazi A, van der Walt J, Gianelli U, Hebeda KM (2018) Histiocytic cell neoplasms involving the bone marrow: summary of the workshop cases submitted to the 18th Meeting of the European Association for Haematopathology (EAHP) organized by the European Bone Marrow Working Group, Basel 2016. Ann Hematol 97:2117–2128. https://doi.org/10.1007/s00277-018-3436-0CrossRefPubMedPubMedCentral

21.

Marsh RA, Haddad E (2018) How i treat primary haemophagocytic lymphohistiocytosis. Br J Haematol 182:185–199. https://doi.org/10.1111/bjh.15274CrossRefPubMed

22.

Alaggio R, Amador C, Anagnostopoulos I, Attygalle AD, Araujo IBO, Berti E, Bhagat G, Borges AM, Boyer D, Calaminici M, Chadburn A, Chan JKC, Cheuk W, Chng WJ, Choi JK, Chuang SS, Coupland SE, Czader M, Dave SS, de Jong D, Du MQ, Elenitoba-Johnson KS, Ferry J, Geyer J, Gratzinger D, Guitart J, Gujral S, Harris M, Harrison CJ, Hartmann S, Hochhaus A, Jansen PM, Karube K, Kempf W, Khoury J, Kimura H, Klapper W, Kovach AE, Kumar S, Lazar AJ, Lazzi S, Leoncini L, Leung N, Leventaki V, Li XQ, Lim MS, Liu WP, Louissaint A, Jr., Marcogliese A, Medeiros LJ, Michal M, Miranda RN, Mitteldorf C, Montes-Moreno S, Morice W, Nardi V, Naresh KN, Natkunam Y, Ng SB, Oschlies I, Ott G, Parrens M, Pulitzer M, Rajkumar SV, Rawstron AC, Rech K, Rosenwald A, Said J, Sarkozy C, Sayed S, Saygin C, Schuh A, Sewell W, Siebert R, Sohani AR, Tooze R, Traverse-Glehen A, Vega F, Vergier B, Wechalekar AD, Wood B, Xerri L, Xiao W (2022) The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms. Leukemia 36:1720–1748. https://doi.org/10.1038/s41375-022-01620-2

23.

WHO Classification of Tumours Editorial Board (2024) Haematolymphoid tumours. International Agency for Research on Cancer, Lyon (France)

24.

Campo E, Jaffe ES, Cook JR, Quintanilla-Martinez L, Swerdlow SH, Anderson KC, Brousset P, Cerroni L, de Leval L, Dirnhofer S, Dogan A, Feldman AL, Fend F, Friedberg JW, Gaulard P, Ghia P, Horwitz SM, King RL, Salles G, San-Miguel J, Seymour JF, Treon SP, Vose JM, Zucca E, Advani R, Ansell S, Au WY, Barrionuevo C, Bergsagel L, Chan WC, Cohen JI, d’Amore F, Davies A, Falini B, Ghobrial IM, Goodlad JR, Gribben JG, Hsi ED, Kahl BS, Kim WS, Kumar S, LaCasce AS, Laurent C, Lenz G, Leonard JP, Link MP, Lopez-Guillermo A, Mateos MV, Macintyre E, Melnick AM, Morschhauser F, Nakamura S, Narbaitz M, Pavlovsky A, Pileri SA, Piris M, Pro B, Rajkumar V, Rosen ST, Sander B, Sehn L, Shipp MA, Smith SM, Staudt LM, Thieblemont C, Tousseyn T, Wilson WH, Yoshino T, Zinzani PL, Dreyling M, Scott DW, Winter JN, Zelenetz AD (2022) The international consensus classification of mature lymphoid neoplasms: a report from the clinical advisory committee. Blood 140:1229–1253. https://doi.org/10.1182/blood.2022015851CrossRefPubMedPubMedCentral

25.

Emile JF, Abla O, Fraitag S, Horne A, Haroche J, Donadieu J, Requena-Caballero L, Jordan MB, Abdel-Wahab O, Allen CE, Charlotte F, Diamond EL, Egeler RM, Fischer A, Herrera JG, Henter JI, Janku F, Merad M, Picarsic J, Rodriguez-Galindo C, Rollins BJ, Tazi A, Vassallo R, Weiss LM, Histiocyte S (2016) Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages. Blood 127:2672–2681. https://doi.org/10.1182/blood-2016-01-690636CrossRefPubMedPubMedCentral

26.

Canna SW, Marsh RA (2020) Pediatric hemophagocytic lymphohistiocytosis. Blood 135:1332–1343. https://doi.org/10.1182/blood.2019000936CrossRefPubMedPubMedCentral

27.

Henter JI, Sieni E, Eriksson J, Bergsten E, Hed Myrberg I, Canna SW, Coniglio ML, Cron RQ, Kernan KF, Kumar AR, Lehmberg K, Minoia F, Naqvi A, Ravelli A, Tang YM, Bottai M, Bryceson YT, Horne A, Jordan MB (2024) Diagnostic guidelines for familial hemophagocytic lymphohistiocytosis revisited. Blood 144:2308–2318. https://doi.org/10.1182/blood.2024025077CrossRefPubMedPubMedCentral

28.

Jordan MB (2024) Hemophagocytic lymphohistiocytosis: a disorder of T cell activation, immune regulation, and distinctive immunopathology. Immunol Rev 322:339–350. https://doi.org/10.1111/imr.13298CrossRefPubMed

29.

Gadoury-Levesque V, Dong L, Su R, Chen J, Zhang K, Risma KA, Marsh RA, Sun M (2020) Frequency and spectrum of disease-causing variants in 1892 patients with suspected genetic HLH disorders. Blood Adv 4:2578–2594. https://doi.org/10.1182/bloodadvances.2020001605CrossRefPubMedPubMedCentral

30.

Kikuchi A, Singh K, Gars E, Ohgami RS (2022) Pathology updates and diagnostic approaches to haemophagocytic lymphohistiocytosis. Histopathology 80:616–626. https://doi.org/10.1111/his.14591CrossRefPubMed

31.

Gurunathan A, Boucher AA, Mark M, Prus KM, O’Brien MM, Breese EH, Mizukawa BE, Absalon MJ, Nelson AS, Jordan MB, Grimley MS, Lorsbach RB, Rotz SJ, Mathanda R, Kumar AR (2018) Limitations of HLH-2004 criteria in distinguishing malignancy-associated hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer 65:e27400. https://doi.org/10.1002/pbc.27400CrossRefPubMed

32.

Henter JI, Horne A, Aricó M, Egeler RM, Filipovich AH, Imashuku S, Ladisch S, McClain K, Webb D, Winiarski J, Janka G (2007) HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer 48:124–131. https://doi.org/10.1002/pbc.21039CrossRefPubMed

33.

Machaczka M, Klimkowska M, Chiang SC, Meeths M, Müller ML, Gustafsson B, Henter JI, Bryceson YT (2013) Development of classical Hodgkin’s lymphoma in an adult with biallelic STXBP2 mutations. Haematologica 98:760–764. https://doi.org/10.3324/haematol.2012.073098CrossRefPubMedPubMedCentral

34.

Meeths M, Entesarian M, Al-Herz W, Chiang SC, Wood SM, Al-Ateeqi W, Almazan F, Boelens JJ, Hasle H, Ifversen M, Lund B, van den Berg JM, Gustafsson B, Hjelmqvist H, Nordenskjöld M, Bryceson YT, Henter JI (2010) Spectrum of clinical presentations in familial hemophagocytic lymphohistiocytosis type 5 patients with mutations in STXBP2. Blood 116:2635–2643. https://doi.org/10.1182/blood-2010-05-282541CrossRefPubMed

35.

Zhang K, Jordan MB, Marsh RA, Johnson JA, Kissell D, Meller J, Villanueva J, Risma KA, Wei Q, Klein PS, Filipovich AH (2011) Hypomorphic mutations in PRF1, MUNC13-4, and STXBP2 are associated with adult-onset familial HLH. Blood 118:5794–5798. https://doi.org/10.1182/blood-2011-07-370148CrossRefPubMedPubMedCentral

36.

Dojcinov SD, Fend F, Quintanilla-Martinez L (2018) EBV-positive lymphoproliferations of B- T- and NK-cell derivation in non-immunocompromised hosts. Pathogens 7:28. https://doi.org/10.3390/pathogens7010028CrossRefPubMedPubMedCentral

37.

Quintanilla-Martinez L, Kumar S, Fend F, Reyes E, Teruya-Feldstein J, Kingma DW, Sorbara L, Raffeld M, Straus SE, Jaffe ES (2000) Fulminant EBV(+) T-cell lymphoproliferative disorder following acute/chronic EBV infection: a distinct clinicopathologic syndrome. Blood 96:443–451CrossRefPubMed

38.

Quintanilla-Martinez L, Swerdlow SH, Tousseyn T, Barrionuevo C, Nakamura S, Jaffe ES (2023) New concepts in EBV-associated B, T, and NK cell lymphoproliferative disorders. Virchows Arch 482:227–244. https://doi.org/10.1007/s00428-022-03414-4CrossRefPubMed

39.

Smith MC, Cohen DN, Greig B, Yenamandra A, Vnencak-Jones C, Thompson MA, Kim AS (2014) The ambiguous boundary between EBV-related hemophagocytic lymphohistiocytosis and systemic EBV-driven T cell lymphoproliferative disorder. Int J Clin Exp Pathol 7:5738–5749PubMedPubMedCentral

40.

Imashuku S, Hibi S, Tabata Y, Itoh E, Hashida T, Tsunamoto K, Ishimoto K, Kawano F (2000) Outcome of clonal hemophagocytic lymphohistiocytosis: analysis of 32 cases. Leuk Lymphoma 37:577–584. https://doi.org/10.3109/10428190009058510CrossRefPubMed

41.

Chua TH, Takano A (2022) Pathological findings in COVID-19 and non-COVID-19 vaccine-associated lymphadenopathy: a systematic review. J Clin Med 11:6290. https://doi.org/10.3390/jcm11216290CrossRefPubMedPubMedCentral

42.

Hamamoto Y, Kawamura M, Mori H, Uchida H, Hiramatsu K, Katori C, Asai H, Kawasaki H, Minamino T, Hashimoto M, Nakatsuka SI, Yoshida K (2024) Kikuchi disease after SARS-CoV-2 vaccination: a case report with immunohistochemical analyses. Int J Surg Pathol 32:1123–1128. https://doi.org/10.1177/10668969231212428CrossRefPubMed

43.

Tintle S, Chen M (2021) Lymphadenopathy with florid lymphoid and Langerhans cell hyperplasia and hemophagocytosis mimicking lymphoma after COVID-19 mRNA vaccination. EJHaem 2:845–847. https://doi.org/10.1002/jha2.265CrossRefPubMedPubMedCentral

44.

Chang KTE, Tay AZE, Kuick CH, Chen H, Algar E, Taubenheim N, Campbell J, Mechinaud F, Campbell M, Super L, Chantranuwat C, Yuen ST, Chan JKC, Chow CW (2019) ALK-positive histiocytosis: an expanded clinicopathologic spectrum and frequent presence of KIF5B-ALK fusion. Mod Pathol 32:598–608. https://doi.org/10.1038/s41379-018-0168-6CrossRefPubMed

45.

Mobarki M, Papoudou-Bai A, Dumollard JM, Alhazmi AH, Musawi S, Madkhali MA, Muqri KY, Péoc’h M, Karpathiou G (2023) Crystal-storing histiocytosis: the Iceberg of more serious conditions. Diagnostics 13(2):271. https://doi.org/10.3390/diagnostics13020271CrossRefPubMedPubMedCentral

46.

West RB, Rubin BP, Miller MA, Subramanian S, Kaygusuz G, Montgomery K, Zhu S, Marinelli RJ, De Luca A, Downs-Kelly E, Goldblum JR, Corless CL, Brown PO, Gilks CB, Nielsen TO, Huntsman D, van de Rijn M (2006) A landscape effect in tenosynovial giant-cell tumor from activation of CSF1 expression by a translocation in a minority of tumor cells. Proc Natl Acad Sci U S A 103:690–695. https://doi.org/10.1073/pnas.0507321103CrossRefPubMedPubMedCentral

47.

Helias-Rodzewicz Z, Donadieu J, Terrones N, Barkaoui MA, Lambilliotte A, Moshous D, Thomas C, Azarnoush S, Pasquet M, Mansuy L, Aladjidi N, Jeziorski E, Marec-Berard P, Gilibert-Yvert M, Spiegel A, Saultier P, Pellier I, Pagnier A, Pertuisel S, Poiree M, Bodet D, Millot F, Isfan F, Stephan JL, Leruste A, Rigaud C, Filhon B, Carausu L, Reguerre Y, Kieffer I, Brichard B, Ben Jannet R, Bakari M, Idbaih A, Bodemer C, Cohen-Aubart F, Haroche J, Tazi A, Boudjemaa S, Fraitag S, Emile JF, Heritier S, French Histiocytosis Study G (2023) Molecular and clinicopathologic characterization of pediatric histiocytoses. Am J Hematol 98:1058–1069. https://doi.org/10.1002/ajh.26938CrossRefPubMed

48.

Chakraborty R, Burke TM, Hampton OA, Zinn DJ, Lim KP, Abhyankar H, Scull B, Kumar V, Kakkar N, Wheeler DA, Roy A, Poulikakos PI, Merad M, McClain KL, Parsons DW, Allen CE (2016) Alternative genetic mechanisms of BRAF activation in Langerhans cell histiocytosis. Blood 128:2533–2537. https://doi.org/10.1182/blood-2016-08-733790CrossRefPubMedPubMedCentral

49.

Durham BH, Lopez Rodrigo E, Picarsic J, Abramson D, Rotemberg V, De Munck S, Pannecoucke E, Lu SX, Pastore A, Yoshimi A, Mandelker D, Ceyhan-Birsoy O, Ulaner GA, Walsh M, Yabe M, Petrova-Drus K, Arcila ME, Ladanyi M, Solit DB, Berger MF, Hyman DM, Lacouture ME, Erickson C, Saganty R, Ki M, Dunkel IJ, Santa-Maria Lopez V, Mora J, Haroche J, Emile JF, Decaux O, Geissmann F, Savvides SN, Drilon A, Diamond EL, Abdel-Wahab O (2019) Activating mutations in CSF1R and additional receptor tyrosine kinases in histiocytic neoplasms. Nat Med 25:1839–1842. https://doi.org/10.1038/s41591-019-0653-6CrossRefPubMedPubMedCentral

50.

Agaimy A, Bonert M, Naqvi A, Wang C, Trpkov K, Dettmar P, Wintzer HO, Stoehr R, Hes O, Williamson SR, Gibson IW, Hartmann A (2020) Langerhans cell histiocytosis associated with renal cell carcinoma is a neoplastic process: clinicopathologic and molecular study of 7 cases. Am J Surg Pathol 44:1658–1665. https://doi.org/10.1097/PAS.0000000000001562CrossRefPubMed

51.

West DS, Dogan A, Quint PS, Tricker-Klar ML, Porcher JC, Ketterling RP, Law ME, McPhail ED, Viswanatha DS, Kurtin PJ, Dao LN, Ritzer RD, Nowakowski GS, Feldman AL (2013) Clonally related follicular lymphomas and Langerhans cell neoplasms: expanding the spectrum of transdifferentiation. Am J Surg Pathol 37:978–986. https://doi.org/10.1097/PAS.0b013e318283099fCrossRefPubMed

52.

Ozkaya N, Melloul Benizri S, Venkataraman G, Karai LJ, Fraitag S, Razanamahery J, Pittaluga S, Battistella M, Pack S, Le Pelletier F, Xi L, Moreau A, Lee I, Helias-Rodzewicz Z, Donadieu J, Haroche J, Raffeld M, Jaffe ES, Emile JF (2024) Indeterminate DC histiocytosis is distinct from LCH and often associated with other hematopoietic neoplasms. Blood Adv 8:5796–5805. https://doi.org/10.1182/bloodadvances.2024013545CrossRefPubMedPubMedCentral

53.

Wood GS, Hu CH, Beckstead JH, Turner RR, Winkelmann RK (1985) The indeterminate cell proliferative disorder: report of a case manifesting as an unusual cutaneous histiocytosis. J Dermatol Surg Oncol 11:1111–1119. https://doi.org/10.1111/j.1524-4725.1985.tb01399.xCrossRefPubMed

54.

Zanella S, Berti E, Bonometti A, for Associazione Italiana Ricerca Istiocitosi O, (2023) Indeterminate cell histiocytosis: a systematic review of the literature with a comprehensive revision of clinical, histopathological, and molecular features. J Eur Acad Dermatol Venereol. https://doi.org/10.1111/jdv.19095CrossRefPubMed

55.

Vener C, Soligo D, Berti E, Gianelli U, Servida F, Ceretti E, Caputo R, Passoni E, Lambertenghi Deliliers G (2007) Indeterminate cell histiocytosis in association with later occurrence of acute myeloblastic leukaemia. Br J Dermatol 156:1357–1361. https://doi.org/10.1111/j.1365-2133.2007.07880.xCrossRefPubMed

56.

Estrada-Veras JI, O’Brien KJ, Boyd LC, Dave RH, Durham B, Xi L, Malayeri AA, Chen MY, Gardner PJ, Alvarado-Enriquez JR, Shah N, Abdel-Wahab O, Gochuico BR, Raffeld M, Jaffe ES, Gahl WA (2017) The clinical spectrum of Erdheim-Chester disease: an observational cohort study. Blood Adv 1:357–366. https://doi.org/10.1182/bloodadvances.2016001784CrossRefPubMedPubMedCentral

57.

Goyal G, Heaney ML, Collin M, Cohen-Aubart F, Vaglio A, Durham BH, Hershkovitz-Rokah O, Girschikofsky M, Jacobsen ED, Toyama K, Goodman AM, Hendrie P, Cao XX, Estrada-Veras JI, Shpilberg O, Abdo A, Kurokawa M, Dagna L, McClain KL, Mazor RD, Picarsic J, Janku F, Go RS, Haroche J, Diamond EL (2020) Erdheim-Chester disease: consensus recommendations for evaluation, diagnosis, and treatment in the molecular era. Blood 135:1929–1945. https://doi.org/10.1182/blood.2019003507CrossRefPubMed

58.

Pegoraro F, Papo M, Cohen-Aubart F, Peyronel F, Lugli G, Trambusti I, Baulier G, de Menthon M, Le Scornet T, Oziol E, Ferreira-Maldent N, Hermine O, Faucher B, Koschel D, Straetmans N, Abisror N, Terrier B, Lifermann F, Razanamahery J, Allenbach Y, Keraen J, Bulifon S, Hervier B, Buccoliero A, Charlotte F, Monzani Q, Boussouar S, Shor N, Tondo A, Barete S, Idbaih A, Tazi A, Sieni E, Amoura Z, Emile JF, Vaglio A, Haroche J (2024) Long-term outcome and prognosis of mixed histiocytosis (Erdheim-Chester disease and Langerhans Cell Histiocytosis). EClinicalMedicine 73:102658. https://doi.org/10.1016/j.eclinm.2024.102658CrossRefPubMedPubMedCentral

59.

Melloul S, Helias-Rodzewicz Z, Cohen-Aubart F, Charlotte F, Fraitag S, Terrones N, Riller Q, Chazal T, Heritier S, Moreau A, Kambouchner M, Copin MC, Donadieu J, Taly V, Amoura Z, Haroche J, Emile JF (2019) Highly sensitive methods are required to detect mutations in histiocytoses. Haematologica 104:e97–e99. https://doi.org/10.3324/haematol.2018.201194CrossRefPubMedPubMedCentral

60.

Fraitag S, Emile JF (2022) Cutaneous histiocytoses in children. Histopathology 80:196–215. https://doi.org/10.1111/his.14569CrossRefPubMed

61.

Picarsic J, Pysher T, Zhou H, Fluchel M, Pettit T, Whitehead M, Surrey LF, Harding B, Goldstein G, Fellig Y, Weintraub M, Mobley BC, Sharples PM, Sulis ML, Diamond EL, Jaffe R, Shekdar K, Santi M (2019) BRAF V600E mutation in Juvenile Xanthogranuloma family neoplasms of the central nervous system (CNS-JXG): a revised diagnostic algorithm to include pediatric Erdheim-Chester disease. Acta Neuropathol Commun 7:168. https://doi.org/10.1186/s40478-019-0811-6CrossRefPubMedPubMedCentral

62.

Salari B, Dehner LP (2022) Juvenile and adult xanthogranuloma: a 30-year single-center experience and review of the disorder and its relationship to other histiocytoses. Ann Diagn Pathol 58:151940. https://doi.org/10.1016/j.anndiagpath.2022.151940CrossRefPubMed

63.

Castro EC, Blazquez C, Boyd J, Correa H, de Chadarevian JP, Felgar RE, Graf N, Levy N, Lowe EJ, Manning JT Jr, Proytcheva MA, Senger C, Shayan K, Sterba J, Werner A, Surti U, Jaffe R (2010) Clinicopathologic features of histiocytic lesions following ALL, with a review of the literature. Pediatr Dev Pathol 13:225–237. https://doi.org/10.2350/09-03-0622-OA.1CrossRefPubMed

64.

Bonometti A, Berti E, for Associazione Italiana Ricerca Istiocitosi O (2020) Reticulohistiocytoses: a revision of the full spectrum. J Eur Acad Dermatol Venereol 34:1684–1694. https://doi.org/10.1111/jdv.16214CrossRefPubMed

65.

Murakami N, Sakai T, Arai E, Muramatsu H, Ichikawa D, Asai S, Shimoyama Y, Ishiguro N, Takahashi Y, Okuno Y, Nishida Y (2020) Targetable driver mutations in multicentric reticulohistiocytosis. Haematologica 105:e61–e64. https://doi.org/10.3324/haematol.2019.218735CrossRefPubMedPubMedCentral

66.

Wick MR, Patterson JW (2019) Cutaneous paraneoplastic syndromes. Semin Diagn Pathol 36:211–228. https://doi.org/10.1053/j.semdp.2019.01.001CrossRefPubMed

67.

Abla O, Jacobsen E, Picarsic J, Krenova Z, Jaffe R, Emile JF, Durham BH, Braier J, Charlotte F, Donadieu J, Cohen-Aubart F, Rodriguez-Galindo C, Allen C, Whitlock JA, Weitzman S, McClain KL, Haroche J, Diamond EL (2018) Consensus recommendations for the diagnosis and clinical management of Rosai-Dorfman-Destombes disease. Blood 131:2877–2890. https://doi.org/10.1182/blood-2018-03-839753CrossRefPubMedPubMedCentral

68.

Goyal G, Young JR, Koster MJ, Tobin WO, Vassallo R, Ryu JH, Davidge-Pitts CJ, Hurtado MD, Ravindran A, Sartori Valinotti JC, Bennani NN, Shah MV, Rech KL, Go RS, Mayo Clinic Histiocytosis Working G (2019) The Mayo Clinic Histiocytosis Working Group consensus statement for the diagnosis and evaluation of adult patients with histiocytic neoplasms: Erdheim-Chester disease, Langerhans cell histiocytosis, and Rosai-Dorfman disease. Mayo Clin Proc 94:2054–2071. https://doi.org/10.1016/j.mayocp.2019.02.023CrossRefPubMed

69.

Ravindran A, Rech KL (2023) How I diagnose Rosai-Dorfman disease. Am J Clin Pathol 160:1–10. https://doi.org/10.1093/ajcp/aqad047CrossRefPubMed

70.

Baraban E, Sadigh S, Rosenbaum J, Van Arnam J, Bogusz AM, Mehr C, Bagg A (2019) Cyclin D1 expression and novel mutational findings in Rosai-Dorfman disease. Br J Haematol 186:837–844. https://doi.org/10.1111/bjh.16006CrossRefPubMed

71.

Jacobsen E, Shanmugam V, Jagannathan J (2017) Rosai-Dorfman disease with activating KRAS mutation - response to cobimetinib. N Engl J Med 377:2398–2399. https://doi.org/10.1056/NEJMc1713676CrossRefPubMed

72.

Ravindran A, Goyal G, Go RS, Rech KL, Working MCH, G, (2021) Rosai-Dorfman disease displays a unique monocyte-macrophage phenotype characterized by expression of OCT2. Am J Surg Pathol 45:35–44. https://doi.org/10.1097/PAS.0000000000001617CrossRefPubMed

73.

Ungureanu IA, Cohen-Aubart F, Heritier S, Haroche J, Donadieu J, Emile JF (2023) PU.1 is a useful nuclear marker to distinguish between histiocytosis and histiocyte-rich tumours. Histopathology 83:320–325. https://doi.org/10.1111/his.14909CrossRefPubMed

74.

Calvo KR, Price S, Braylan RC, Oliveira JB, Lenardo M, Fleisher TA, Rao VK (2015) JMML and RALD (Ras-associated autoimmune leukoproliferative disorder): common genetic etiology yet clinically distinct entities. Blood 125:2753–2758. https://doi.org/10.1182/blood-2014-11-567917CrossRefPubMedPubMedCentral

75.

Maric I, Pittaluga S, Dale JK, Niemela JE, Delsol G, Diment J, Rosai J, Raffeld M, Puck JM, Straus SE, Jaffe ES (2005) Histologic features of sinus histiocytosis with massive lymphadenopathy in patients with autoimmune lymphoproliferative syndrome. Am J Surg Pathol 29:903–911. https://doi.org/10.1097/01.pas.0000157997.61177.08CrossRefPubMed

76.

Kemps PG, Picarsic J, Durham BH, Helias-Rodzewicz Z, Hiemcke-Jiwa L, van den Bos C, van de Wetering MD, van Noesel CJM, van Laar JAM, Verdijk RM, Flucke UE, Hogendoorn PCW, Woei AJF, Sciot R, Beilken A, Feuerhake F, Ebinger M, Mohle R, Fend F, Bornemann A, Wiegering V, Ernestus K, Mery T, Gryniewicz-Kwiatkowska O, Dembowska-Baginska B, Evseev DA, Potapenko V, Baykov VV, Gaspari S, Rossi S, Gessi M, Tamburrini G, Heritier S, Donadieu J, Bonneau-Lagacherie J, Lamaison C, Farnault L, Fraitag S, Jullie ML, Haroche J, Collin M, Allotey J, Madni M, Turner K, Picton S, Barbaro PM, Poulin A, Tam IS, El Demellawy D, Empringham B, Whitlock JA, Raghunathan A, Swanson AA, Suchi M, Brandt JM, Yaseen NR, Weinstein JL, Eldem I, Sisk BA, Sridhar V, Atkinson M, Massoth LR, Hornick JL, Alexandrescu S, Yeo KK, Petrova-Drus K, Peeke SZ, Munoz-Arcos LS, Leino DG, Grier DD, Lorsbach R, Roy S, Kumar AR, Garg S, Tiwari N, Schafernak KT, Henry MM, van Halteren AGS, Abla O, Diamond EL, Emile JF (2022) ALK-positive histiocytosis: a new clinicopathologic spectrum highlighting neurologic involvement and responses to ALK inhibition. Blood 139:256–280. https://doi.org/10.1182/blood.2021013338CrossRefPubMedPubMedCentral

77.

Chan JK, Lamant L, Algar E, Delsol G, Tsang WY, Lee KC, Tiedemann K, Chow CW (2008) ALK+ histiocytosis: a novel type of systemic histiocytic proliferative disorder of early infancy. Blood 112:2965–2968. https://doi.org/10.1182/blood-2008-03-147017CrossRefPubMed

78.

Doyle LA, Marino-Enriquez A, Fletcher CD, Hornick JL (2015) ALK rearrangement and overexpression in epithelioid fibrous histiocytoma. Mod Pathol 28:904–912. https://doi.org/10.1038/modpathol.2015.49CrossRefPubMed

Title: Histiocytoses and reactive proliferations of histiocytes: current state of the art and evolving concepts—a report from the joint CSHP-EA4HP-SH workshop 2024, Hefei, China
Authors: Falko Fend
Stefan Dirnhofer
Caoimhe Egan
Sophie Song
Zhe Wang
Xiaoqiu Li
Weiping Liu
Wenbin Xiao
Jean-Francois Emile
John Goodlad
Robert Lorsbach
Publication date: 10-04-2025
Publisher: Springer Berlin Heidelberg
Keywords: Histiocytosis
Hemophagocytic Lymphohistiocytosis
Hemophagocytic Lymphohistiocytosis
Langerhans Cell Histiocytosis
Published in: Virchows Archiv
Print ISSN: 0945-6317
Electronic ISSN: 1432-2307
DOI: https://doi.org/10.1007/s00428-025-04096-4

Navigating neuroimaging in Alzheimer disease care

Springer Medicine

Histiocytoses and reactive proliferations of histiocytes: current state of the art and evolving concepts—a report from the joint CSHP-EA4HP-SH workshop 2024, Hefei, China

Abstract

Navigating neuroimaging in Alzheimer disease care

Springer Medicine

Abstract

Please log in to get access to this content